Latest From Medigene AG
Management outlined four new oncology and one rare disease program during an analyst day. CEO Nick Leschly also talked to Scrip about staying focused on R&D as other gene therapy players get bought out.
Roivant has launched its 16th Vant, called Cytovant, which hopes to be Asia's premier cell therapy company. It has inked a deal worth potentially $1bn with Germany's Medigene to develop TCR immunotherapies and a dendritic cell vaccine.
Bluebird has been an active deal maker as it looks to add tools, targets and technological capabilities to its R&D engine. A pair of August TCR-focused deals, including the latest with Gritstone, continue that strategy.
Looking back at the second quarter, PharmaVitae analysts have selected 10 biopharma companies with market caps under $3bn they think are primed for acquisition – and the likely candidates for a buy-out.
Drug Discovery Tools
- Natural Products
- Molecular Diversity
- Gene Therapy, Cell Therapy
- Large Molecule
- Drug Discovery Tools
- Therapeutic Areas
- Immune Disorders
- Infectious & Viral Diseases
- Western Europe
- Parent & Subsidiaries
- Medigene AG
- Senior Management
Dolores Schendel , PhD, CEO & CSO
Axel-Sven Malkomes , CFO & Chief Bus. Dev. Officer
Kai Pinkernell, MD, CMO & Chief Dev. Officer
- Contact Info
Phone: (49) 89 20 00 33 0
Lochhamer Str. 11
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.